Spondyloarthritis & psoriatic arthritis

Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study

Scand J RheumatolPublished Retrospective cohort study

Main finding · Composite CVD (co-primary)Result — go to the resultHazard ratio 1.17

Authors' conclusion

We did not find significant differences in the risks of CVD and GIB between celecoxib and nsNSAIDs in AS patients.

Study context

Population
Adult ankylosing spondylitis (AS) patients newly prescribed non-steroidal anti-inflammatory drugs (NSAIDs) continuously for ≥ 30 days, 2013–2017, Korean Health Insurance Review and Assessment database3,164 celecoxib, 18,924 nsNSAID before matching
Participants
3,047 vs 3,047
Exposure
Celecoxib vs non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs)
  • Celecoxibn = 3,047
  • nsNSAIDsn = 3,047reference
Outcome
Co-primary: composite CVD events (hospitalization for MI, ischaemic heart disease, stroke, transient ischaemic attack, HF, coronary revascularization) and composite GIB (hospitalization for upper and lower GIB)
Methodological detailsnationwide, propensity-score matched (1:1)
  • Nationwide
  • Propensity-score matched (1:1)

Main finding

Composite CVD (co-primary)

Hazard ratio

1.17

P = 0.499

By group

As reported in the abstract

Observational data: associations, not effects.

Further findings

Co-primary: composite GIB · propensity-score matched

HR 0.87 · P = 0.696

Each component of composite cardiovascular disease (CVD) and gastrointestinal bleeding (GIB)

No significant differences between the two groups

Original publication

Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study. Scand J Rheumatol. Published 3 March 2025. doi:10.1080/03009742.2025.2467556

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.